• Login
  • Register
Nairametrics
  • Home
  • Exclusives
    • Financial Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Metrics
    • Economy
    • Nairalytics
  • Markets
    • Currencies
    • Cryptos
    • Commodities
    • Equities
      • Company Results
      • Dividends
      • Stock Market
    • Fixed Income
    • Market Views
    • Securities
  • Sectors
    • Agriculture
    • Aviation
    • Company News
    • Consumer Goods
    • Corporate Updates
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Health
    • Hospitality & Travel
    • Manufacturing
    • Real Estate and Construction
    • Renewables & Sustainability
    • Tech News
  • Business News
    • Budget
    • Public Debt
    • Funds Management
    • Tax
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Op-Eds
    • Research Analysis
  • Recapitalization
    • Access Holdings Offer
    • Fidelity Bank Offer
    • GTCO Offer
    • Zenith Bank Offer
  • Home
  • Exclusives
    • Financial Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Metrics
    • Economy
    • Nairalytics
  • Markets
    • Currencies
    • Cryptos
    • Commodities
    • Equities
      • Company Results
      • Dividends
      • Stock Market
    • Fixed Income
    • Market Views
    • Securities
  • Sectors
    • Agriculture
    • Aviation
    • Company News
    • Consumer Goods
    • Corporate Updates
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Health
    • Hospitality & Travel
    • Manufacturing
    • Real Estate and Construction
    • Renewables & Sustainability
    • Tech News
  • Business News
    • Budget
    • Public Debt
    • Funds Management
    • Tax
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Op-Eds
    • Research Analysis
  • Recapitalization
    • Access Holdings Offer
    • Fidelity Bank Offer
    • GTCO Offer
    • Zenith Bank Offer
Nairametrics
No Result
View All Result
Home Economy Socio Economic

Pfizer, BioNTech submit data for authorisation of COVID-19 vaccine in young children

Chidinma Anyalewechi by Chidinma Anyalewechi
September 29, 2021
in Socio Economic
Trials for homegrown mRNA COVID-19 shot approved in India

FILE PHOTO: A woman holds a small bottle labelled with a "Coronavirus COVID-19 Vaccine" sticker and a medical syringe in this illustration taken October 30, 2020. REUTERS/Dado Ruvic/File Photo

Share on FacebookShare on TwitterShare on Linkedin

On Tuesday, drugmakers Pfizer and BioNTech commenced submission of data to the US Food and Drug Administration for their authorisation of their COVID-19 vaccine for children ages 5- 11 (five to 11).

This was a progressive move considering the increased number of infections amongst children, a large number of whom have been infected since the emergence of the Delta variant.

Medical experts have claimed severally that immunizing this age group would be key and paramount to keeping schools and educational environments open, as well as reducing the effect of the pandemic.

RelatedStories

Pfizer withdraws $125,000 sickle cell treatment Oxbryta worldwide 

Pfizer withdraws $125,000 sickle cell treatment Oxbryta worldwide 

September 26, 2024
Pfizer

Pfizer shares plunge 7% as 2024 revenue forecast falls below consensus estimates 

December 13, 2023

What they are saying

In a statement released on Tuesday, the company stated that “These data have been shared with the FDA for the Agency’s initial review.”

In addition, “A formal submission to request Emergency Use Authorization (EUA) of the companies COVID-19 vaccine in children 5 to <12 years of age is expected to follow in the coming weeks,” they added, with submissions to the European Medicines Agency and others also planned.

Recall that, a week ago, both companies announced results from a global clinical trial showing that the vaccines were safe and evoked a robust response of neutralizing antibodies, which stop the coronavirus from entering cells.

In the trial conducted for the vaccine, Children in the age group were given a two-dose regimen of 10 micrograms, compared to the 30 micrograms for older age groups. The shots were given 21 days apart.

In the United States, however, the Pfizer vaccine has been fully approved since August for administration and has been available for younger children following a doctor’s prescription.

However, authorities have cautioned doctors against its prescription until its safety data is made publicly available.

The Food and Drug Administration has said a complete review will be initiated after the formal submission of the trial data. It said that the review will likely last for “a matter of weeks rather than months.”

In addition to seeking the approval of vaccines for 5-11-year-old kids, the two drugmakers, Pfizer and BioNTech, are also looking to seek vaccine approval for infants aged six months to two years, and on children aged two to five.

According to information provided by the companies, the data for these groups may come as soon as the “fourth quarter” of the year.

In total, 4,500 children aged six months to 11 years were enrolled in the United States, Finland, Poland, and Spain.

What you should know

This comes after the FDA authorized booster shots of Pfizer and BioNTech’s Covid-19 for people who are 65 years and older and other vulnerable and immunocompromised citizens six months after they complete their first two doses.

The FDA’s Vaccines Advisory Committee, two weeks ago, agreed unanimously to give boosters to older Americans and those who are highly vulnerable and are at high risk of suffering from severe illness should they contract the virus.

Tags: BioNTechCOVID-19 vaccine for childrenPfizerUS Food and Drug Administration
Chidinma Anyalewechi

Chidinma Anyalewechi

For further inquiries about this article, contact: Email: chidinma.anyalewechi@nairametrics.com LinkedIn: linkedin.com/in/chidinma-anyalewechi-a323ab173/

Related Posts

Pfizer withdraws $125,000 sickle cell treatment Oxbryta worldwide 
Health

Pfizer withdraws $125,000 sickle cell treatment Oxbryta worldwide 

September 26, 2024
Pfizer
Company News

Pfizer shares plunge 7% as 2024 revenue forecast falls below consensus estimates 

December 13, 2023
Pfizer loses $10 billion slice from obesity drug market as it discontinues its weight loss pill 
Health

Pfizer loses $10 billion slice from obesity drug market as it discontinues its weight loss pill 

December 5, 2023
Covid-19: Lagos puts 14 countries on watchlist, to enforce travel protocols
Socio Economic

Lagos State Government says Moderna, Pfizer vaccines now available

January 3, 2022
U.S. to receive 500 million more Pfizer-BioNTech vaccine doses for poorer nations
Socio Economic

US donates 2.5 million doses of Pfizer Covid-19 vaccines to Nigeria

December 9, 2021
Health Regulator approves Pfizer COVID-19 vaccine for teenagers in South Africa
Socio Economic

Pfizer reveals 3 doses of its Covid-19 vaccine effective against Omicron

December 8, 2021
Next Post
DEAL: Netflix acquires Night School Studio to create gaming experience for users 

DEAL: Netflix acquires Night School Studio to create gaming experience for users 

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Emple
nlng
first bank
Zenth Bank








DUNS

Recent News

  • Sovereign green bond offer records N91.42 billion, oversubscribed by 183% – DMO 
  • Banks clear 95% of N180 billion USSD debt, 3 lenders still owing – ALTON 
  • BNY Mellon, Standard Bank launch naira-denominated notes for global investors 

Follow us on social media:

Recent News

DMO, FGN Savings Bonds

Sovereign green bond offer records N91.42 billion, oversubscribed by 183% – DMO 

June 19, 2025
Telecom operators moots price review, says current rate unsustainable

Banks clear 95% of N180 billion USSD debt, 3 lenders still owing – ALTON 

June 19, 2025
  • iOS App
  • Android App
  • Contact Us
  • Home
  • Markets
  • Sectors
  • Economy
  • Business News
  • Financial Literacy
  • Disclaimer
  • Ads Disclaimer
  • Copyright Infringement

© 2025 Nairametrics

Welcome Back!

Login to your account below

Forgotten Password? Sign Up

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In
Social Media Auto Publish Powered By : XYZScripts.com
No Result
View All Result
  • Home
  • Exclusives
    • Financial Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Metrics
    • Economy
    • Nairalytics
  • Markets
    • Currencies
    • Cryptos
    • Commodities
    • Equities
      • Company Results
      • Dividends
      • Stock Market
    • Fixed Income
    • Market Views
    • Securities
  • Sectors
    • Agriculture
    • Aviation
    • Company News
    • Consumer Goods
    • Corporate Updates
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Health
    • Hospitality & Travel
    • Manufacturing
    • Real Estate and Construction
    • Renewables & Sustainability
    • Tech News
  • Business News
    • Budget
    • Public Debt
    • Funds Management
    • Tax
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Op-Eds
    • Research Analysis
  • Recapitalization
    • Access Holdings Offer
    • Fidelity Bank Offer
    • GTCO Offer
    • Zenith Bank Offer
  • Login
  • Sign Up

© 2025 Nairametrics